The study
PATHFINDER 2 evaluated the Galleri multicancer detection test in adults aged 50 and older. Its reported test-performance results include a 60.3% positive predictive value and 39.3% sensitivity for cancers diagnosed within 12 months. An FDA advisory panel voted in favor of the test, but that is not FDA approval.
What it means for practice
the 60% PPV and the 70% sensitivity for the deadliest cancers, the next milestone is mortality data, which would determine whether multi-cancer detection earns a place alongside guideline screening.
Source: Karthik V. Giridhar | Nature Medicine | Sep 22, 2026
Originally published in The Longevity Medicine Intelligence newsletter (#108).
WRITTEN BYlongevitydocs™ editorsCurated by the longevitydocs™ editorial team from the weekly newsletter
